Table 1.
The antiproliferative activity of Compounds 1–21 and cisplatin as a reference compound.
| Compound | Human Cell Line/IC50 ± SD (µM) | |||
|---|---|---|---|---|
| C-32 | SNB-19 | MDA-MB-231 | HFF-1 | |
| 1 | 25.0 ± 0.3 | 26.6 ± 0.5 | 31.9 ± 2.7 | 15.6 ± 0.3 |
| 2 a | 22.8 ± 0.7 | 26.2 ± 0.8 | 25.1 ± 3.1 | 15.7 ± 0.5 |
| 3 | 10.5 ± 0.8 | 15.9 ± 0.3 | 23.3 ± 0.3 | 10.0 ± 1.4 |
| 4 | 16.8 ± 0.3 | 18.4 ± 1.7 | 1.4 ± 0.3 | 14.8 ± 0.9 |
| 5 | 4.0 ± 0.1 | 3.8 ± 0.1 | 6.9 ± 1.9 | 3.8 ± 0.8 |
| 6 | 3.2 ± 0.6 | 8.4 ± 1.2 | 21.0 ± 1.5 | 3.9 ± 0.5 |
| 7 a | 0.20 ± 0.1 | 0.4 ± 0.1 | 22.4 ± 2.7 | Neg |
| 8 a | 0.28 ± 0.1 | 0.3 ± 0.1 | 17.2 ± 2.8 | Neg |
| 9 b | 0.32 ± 0.1 | 20.4 ± 0.2 | 21.4 ± 3.4 | 3.3 ± 0.3 |
| 10 | 26.8 ± 1.9 | 19.8 ± 1.4 | 22.2 ± 1.4 | 15.8 ± 1.8 |
| 11 | 168.0 ± 6.2 | 33.8 ± 1.3 | 24.6 ± 2.9 | 20.1 ± 1.2 |
| 12 | 207.6 ± 4.6 | 19.5 ± 1.0 | 17.2 ± 2.5 | 14.0 ± 2.4 |
| 13 | 22.6 ± 0.8 | 19.9 ± 1.4 | 22.6 ± 2.3 | 10.8 ± 0.5 |
| 14 | 10.6 ± 0.6 | 19.6 ± 1.0 | 17.9 ± 0.8 | 4.4 ± 0.9 |
| 15 | 21.7 ± 0.6 | 18.6 ± 0.7 | 26.1 ± 0.3 | 13.5 ± 1.3 |
| 16 a | 1.1 ± 0.1 | 0.7 ± 0.02 | 3.0 ± 0.3 | Neg |
| 17 a | 1.5 ± 0.1 | 0.2 ± 0.1 | 12.6 ± 2.7 | Neg |
| 18 b | 0.3 ± 0.1 | 21.7 ± 1.1 | 1.8 ± 0.1 | 12.6 ± 0.9 |
| 19 | 131.4 ± 2.4 | 25.7 ± 1.4 | 71.3 ± 3.9 | 17.8 ± 1.8 |
| 20 | 18.9 ± 1.7 | 16.6 ± 3.0 | 26.8 ± 1.2 | 0.6 ± 0.2 |
| 21 | 21.1 ± 1.2 | 24.5 ± 1.1 | 23.2 ± 1.5 | 14.5 ± 2.6 |
| cisplatin | 16.4 ± 1.2 | 18.9 ± 0.4 | 25.5 ± 0.2 | 9.1 ± 1.8 |